These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 10218956)

  • 1. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity.
    Ly LH; Zhao XY; Holloway L; Feldman D
    Endocrinology; 1999 May; 140(5):2071-6. PubMed ID: 10218956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
    Skowronski RJ; Peehl DM; Feldman D
    Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
    Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
    Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells.
    Barreto AM; Schwartz GG; Woodruff R; Cramer SD
    Cancer Epidemiol Biomarkers Prev; 2000 Mar; 9(3):265-70. PubMed ID: 10750664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constitutive expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in a transformed human proximal tubule cell line: evidence for direct regulation of vitamin D metabolism by calcium.
    Bland R; Walker EA; Hughes SV; Stewart PM; Hewison M
    Endocrinology; 1999 May; 140(5):2027-34. PubMed ID: 10218951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines.
    Skowronski RJ; Peehl DM; Feldman D
    Endocrinology; 1993 May; 132(5):1952-60. PubMed ID: 7682937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
    Zhao XY; Ly LH; Peehl DM; Feldman D
    Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity.
    Swami S; Krishnan AV; Peehl DM; Feldman D
    Mol Cell Endocrinol; 2005 Sep; 241(1-2):49-61. PubMed ID: 15955619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of antiproliferative activity of 1alpha,25-dihydroxyvitamin D3 (analogs) by cytochrome P450 enzyme inhibitors is compound- and cell-type specific.
    Zhao J; Tan BK; Marcelis S; Verstuyf A; Bouillon R
    J Steroid Biochem Mol Biol; 1996 Feb; 57(3-4):197-202. PubMed ID: 8645629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells.
    Zhao XY; Ly LH; Peehl DM; Feldman D
    Endocrinology; 1999 Mar; 140(3):1205-12. PubMed ID: 10067845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines.
    Miller GJ; Stapleton GE; Hedlund TE; Moffat KA
    Clin Cancer Res; 1995 Sep; 1(9):997-1003. PubMed ID: 9816072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway.
    Hedlund TE; Moffatt KA; Miller GJ
    Endocrinology; 1996 May; 137(5):1554-61. PubMed ID: 8612485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer.
    Chen TC; Holick MF; Lokeshwar BL; Burnstein KL; Schwartz GG
    Recent Results Cancer Res; 2003; 164():273-88. PubMed ID: 12899529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S; Agoulnik IU; Weigel NL
    Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3.
    Schwartz GG; Whitlatch LW; Chen TC; Lokeshwar BL; Holick MF
    Cancer Epidemiol Biomarkers Prev; 1998 May; 7(5):391-5. PubMed ID: 9610788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells.
    Swamy N; Chen TC; Peleg S; Dhawan P; Christakos S; Stewart LV; Weigel NL; Mehta RG; Holick MF; Ray R
    Clin Cancer Res; 2004 Dec; 10(23):8018-27. PubMed ID: 15585637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition.
    Hsu JY; Feldman D; McNeal JE; Peehl DM
    Cancer Res; 2001 Apr; 61(7):2852-6. PubMed ID: 11306457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-expression of 1α-hydroxylase and vitamin D receptor in human articular chondrocytes.
    Hansen AK; Figenschau Y; Zubiaurre-Martinez I
    BMC Musculoskelet Disord; 2017 Nov; 18(1):432. PubMed ID: 29110708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiproliferative signalling by 1,25(OH)2D3 in prostate and breast cancer is suppressed by a mechanism involving histone deacetylation.
    Banwell CM; Singh R; Stewart PM; Uskokovic MR; Campbell MJ
    Recent Results Cancer Res; 2003; 164():83-98. PubMed ID: 12899515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
    Zhao XY; Peehl DM; Navone NM; Feldman D
    Endocrinology; 2000 Jul; 141(7):2548-56. PubMed ID: 10875257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.